Advertisement


Tycel J. Phillips, MD, and Alex F. Herrera, MD, on Classical Hodgkin Lymphoma: New Data on Nivolumab, AVD, and Brentuximab Vedotin

2023 ASCO Annual Meeting

Advertisement

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss results from the SWOG S1826 study, which showed that nivolumab and AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free survival vs brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma. Longer follow-up is needed to assess overall survival and patient-reported outcomes. This trial may be a key step toward harmonizing the pediatric and adult treatment of advanced-stage disease (LBA4).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Tycel J. Phillips: I think we're all very excited to see your presentation about this phenomenal treatment in Hodgkin's lymphoma. If you can, in your own words, just give us a little background about what led to the development of this clinical trial. Alex F. Herrera: Absolutely. S1826 was a trial that we started developing several years ago. Back then, the standard treatment for advanced stage Hodgkin's lymphoma was PET-adapted combination chemotherapy, but different regimens were given across the globe. Pediatric patients and adult patients received different regimens. Pediatric patients, actually a majority of them with advanced stage disease, received radiation, consolidative radiation. So the landscape was really varied, and right around that time, brentuximab vedotin became an option in the front-line treatment of advanced stage Hodgkin's lymphoma after ECHELON-1 showed that modified progression-free survival, and ultimately overall survival, was better compared with ABVD. And so that was kind of the landscape when we were developing the trial. We designed S1826 to really be this direct comparison, randomize patients on a 1:1 basis comparing brentuximab vedotin, AVD, which was a standard at that point, compared to PD-1 blockade combined with AVD, so with nivolumab. Tycel J. Phillips: Again, a very bold step, because we talk about all these effective treatments and nobody really ever goes head-to-head and you took on the lion. What about the results? Tell us how this study played out. Well, I would say I appreciate you saying it was a bold step. I think this is exactly the kind of research that we can do in the cooperative groups. This was a huge collaboration across the adult and pediatric cooperative groups to design this study, develop consensus for this study, and make that bold step. In the end, we were rewarded because at a second planned interim analysis, actually, the primary progression-free survival endpoint crossed into the protocol-specified statistical boundary and nivolumab AVD resulted in superior progression-free survival compared to brentuximab AVD. The hazard ratio was 0.48, so it was a dramatic improvement in outcomes. I think you hit the key, dramatic, because obviously a lot of us knew about the study. I don't think any of us expected it to read out this early. How shocked are you about the results and what's next for the field? Alex F. Herrera: Yeah, it was a really dramatic result. One, because it happened so soon, but also because brentuximab vedotin is a really good drug for Hodgkin's lymphoma. And so to see such a large effect was a little surprising. But we also know that PD-1 blockade is a phenomenal drug for the treatment of Hodgkin's lymphoma, and it takes advantage of this genetic vulnerability. Hodgkin's lymphoma has these genetic changes in the PD-1 ligand genes that lead to overexpression of PD-1 ligands on its surface, so it's really a truly targeted therapy. But also, it doesn't have a chemotherapy component. So not only are we improving outcomes, but we're also reducing toxicity. Only 6 out of almost 1,000 patients received radiation. For me, obviously it's exciting that the study was a positive study and the outcomes were improved, but even just the reduction of radiation for such a young population is a win in and of itself. Tycel J. Phillips: I think that last point is a big point. I think we've all argued quite a bit with the role of radiation in patients with Hodgkin's lymphoma and the late complications, and especially given the differences, as you mentioned, between adults and pediatrics. Again, phenomenal. Moving forward with what we have and what we know from this, how do you see treatment evolving in Hodgkin's patients? Alex F. Herrera: It's a great question. I think we're going to continue to follow these patients and there's a regulatory submission that BMS is working on, so you can envision nivolumab AVD becoming the front-line treatment option for advanced Hodgkin's lymphoma. I think the next questions are, actually, there are still several questions. I don't think we could just claim victory and stop here. Brentuximab vedotin is a good drug for Hodgkin's lymphoma. Can we reincorporate it back into front-line therapy? Or is the role in second line? Are the outcomes good enough that we can start to think about deescalation based on biomarkers? I think there's some really exciting questions to ask still. Tycel J. Phillips: Yeah, I think those last two points are very, very interesting and I think we're all quite interested in seeing how this plays out moving forward. I think, for you, this is, again, a great and phenomenal study. Again, I applaud you and thank you for taking time to be with us this afternoon. Alex F. Herrera: Oh, thank you. My pleasure. Honestly, I am, in some ways, just the messenger. This was a huge effort from many, many, many people across the NCTN, but it's exciting, and most of all, exciting for patients, so thank you for taking the time. Tycel J. Phillips: No, I appreciate it. Thank you.

Related Videos

Bladder Cancer

Christian Pfister, MD, PhD, on Bladder Cancer: New Overall Survival Data on Perioperative Chemotherapy

Christian Pfister, MD, PhD, of Rouen University Hospital, discusses phase III results from the VESPER trial, which showed that dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin provided a better overall survival rate at 5 years and improved disease-specific survival compared with gemcitabine as perioperative chemotherapy in patients with muscle-invasive bladder cancer (Abstract LBA4507). 

Lymphoma

Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).

Ajay K. Nooka, MBBS, Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Data for Elranatamab

Ajay K. Nooka, MBBS, of Winship Cancer Center of Emory University, discusses findings from a pooled analysis of MagnetisMM studies. The data showed that, in patients with relapsed or refractory multiple myeloma who have not yet been treated with B-cell maturation antigen–directed therapies, elranatamab was efficacious and well tolerated.

Myelodysplastic Syndromes
Supportive Care

Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept

Aaron T. Gerds, MD, of Cleveland Clinic Taussig Cancer Institute, talks about treating the anemia many patients with myelofibrosis experience because of JAK inhibitor therapy. The ACE-536-MF-001 study showed that luspatercept improved anemia and transfusion burden in this population, with a safety profile consistent with that in previous studies (Abstract 7016).

Kidney Cancer

Thomas E. Hutson, DO, PharmD, on RCC: Overall Survival Analysis of Lenvatinib, Pembrolizumab, and Sunitinib

Thomas E. Hutson, DO, PharmD, of Texas Oncology, discusses the 4-year follow-up results from the CLEAR study for patients with advanced renal cell carcinoma (RCC). The data showed that lenvatinib plus pembrolizumab continues to demonstrate clinically meaningful benefit vs sunitinib in overall and progression-free survival, as well as in overall and complete response rates, in first-line treatment (Abstract 4502).

Advertisement

Advertisement




Advertisement